LEX-WK-D5Z9YD2Ccrawled 2024-02-02 14:36Z
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®
Dominick DiSabatino · Eve Costopoulos · Cortney Inman · Published February 2, 2024
Work details
- author
- Dominick DiSabatino · Eve Costopoulos · Cortney Inman
- firm or organization
- Sheppard, Mullin, Richter & Hampton LLP
- practice area
- Food, Drug & Agriculture
- published
- 2024-02-02
Citation
Dominick DiSabatino, Eve Costopoulos, Cortney Inman, FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® (February 2, 2024) [The Library at LexBlog, LEX-WK-D5Z9YD2C, lexpid.org/D5Z9YD2C]